Details of the Drug Combinations

General Information of This Drug (ID: DMIYHAW)

Drug Name

PU-H71 DMIYHAW

Synonyms

PU-H71; 873436-91-0; PU H71; PU-H 71; UNII-06IVK87M04; CHEMBL200102; 06IVK87M04; 6-amino-8-[(6-iodo-1,3-benzodioxol-5-yl)thio]-n-(1-methylethyl)-9h-purine-9-propanamine; NSC 750424; 8-[(6-Iodo-1,3-Benzodioxol-5-Yl)thio]-9-[3-(Isopropylamino)propyl]-9h-Purin-6-Amine; 8-(6-Iodobenzo[d][1,3]dioxol-5-ylthio)-9-(3-(isopropylamino)propyl)-9H-purin-6-amine; 8-((6-Iodobenzo[d][1,3]dioxol-5-yl)thio)-9-(3-(isopropylamino)propyl)-9H-purin-6-amine; H71; PUH-71; 2fwz; PU-H-71

Indication

Disease Entry	ICD 11	Status	REF
Breast cancer	2C60-2C65	Phase 1	[1]
Myelofibrosis	2A20.2	Phase 1	[1]
Solid tumour/cancer	2A00-2F9Z	Phase 1	[2]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Ruxolitinib + PU-H71	DC22I2A	Ruxolitinib	Myelofibrosis	[3]
------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	NCBI GEO: archive for functional genomics data sets--update. Nucleic Acids Res. 2013 Jan;41(Database issue):D991-5.
3	ClinicalTrials.gov (NCT03373877) Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis